Abstract
Introduction: Aromatase inhibitor (AI)-induced musculoskeletal symptoms (AIMSS) can decrease health-related quality of life and lead to discontinuation of AI therapy for postmenopausal women with breast cancer (BC). Although central sensitization (CS) may contribute to AIMSS, the relevance of CS-related symptoms to AIMSS has not been fully clarified. This study aimed to investigate the relationship between AIMSS and CS-related symptoms in women with BC who received AI therapy. Methods: This cross-sectional study recruited women who underwent BC surgery before at least 1 year and were taking AI for at least 6 months. Participants were assessed for joint pain and CS-related symptoms using the central sensitization inventory (CSI). The severity of CS-related symptoms was classified into three groups, and the prevalence of AIMSS was calculated. Multiple logistic regression analysis was used to assess the relationship between AIMSS and factors of possible relevance to AIMSS, including CSI severity. Results: Of the 73 women who were included in this study, 31 (42.4%) were categorized into the AIMSS group and 42 (57.6%) into the non-AIMSS group. Participants with a history of chemotherapy and higher CSI score were significantly more likely to have AIMSS. Multiple logistic regression analysis showed that a history of chemotherapy (odds ratio = 4.21) and higher CSI severity (odds ratio = 13.43) had significantly associated with AIMSS. Conclusion: CS-related symptoms assessed using CSI may be strongly associated with AIMSS. Further longitudinal studies to investigate the causal relationship and effectiveness of CS-targeted interventions are needed to prevent and treat AIMSS effectively.
Journal Section:
Research Article
References
1.
Winer
EP
, Hudis
C
, Burstein
HJ
, Wolff
AC
, Pritchard
KI
, Ingle
JN
, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
. J Clin Oncol
. 2005
;23
(3
):619
–29
. 2.
Burstein
HJ
, Lacchetti
C
, Anderson
H
, Buchholz
TA
, Davidson
NE
, Gelmon
KA
, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update
. J Clin Oncol
. 2019
;37
(5
):423
–38
. 3.
Early Breast Cancer Trialists’ Collaborative Group EBCTCG
. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
. Lancet
. 2015
;386
(10001
):1341
–52
. 4.
Goss
PE
, Ingle
JN
, Pritchard
KI
, Robert
NJ
, Muss
H
, Gralow
J
, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years
. N Eng J Med
. 2016
;375
(3
):209
–19
. 5.
Crew
KD
, Greenlee
H
, Capodice
J
, Raptis
G
, Brafman
L
, Fuentes
D
, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer
. J Clin Oncol
. 2007
;25
:3877
–83
. 6.
Dizdar
O
, Ozçakar
L
, Malas
FU
, Harputluoglu
H
, Bulut
N
, Aksoy
S
, et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia
. J Clin Oncol
. 2009
;27
(30
):4955
–60
. 7.
Beckwee
D
, Leysen
L
, Meuwis
K
, Adriaenssens
N
. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis
. Support Care Cancer
. 2017
;25
(5
):1673
–86
. 8.
Henry
NL
, Giles
JT
, Ang
D
, Mohan
M
, Dadabhoy
D
, Robarge
J
, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
. Breast Cancer Res Treat
. 2008
;111
(2
):365
–72
. 9.
Mao
JJ
, Stricker
C
, Bruner
D
, Xie
S
, Bowman
MA
, Farrar
JT
, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors
. Cancer
. 2009
;115
(16
):3631
–9
. 10.
Lombard
JM
, Zdenkowski
N
, Wells
K
, Beckmore
C
, Reaby
L
, Forbes
JF
, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options
. Support Care Cancer
. 2016
;24
(5
):2139
–46
. 11.
Pineda-Moncusi
M
, servitja
S
, Tusquets
I
, Diez-Perez
A
, Rial
A
, Cos
ML
, et al. Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study
. Breast Cancer Res Treat
. 2019
;177
(1
):53
–60
. 12.
Kanematsu
M
, Morimoto
M
, Honda
J
, Nagao
T
, Nakagawa
M
, Takahashi
M
, et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia
. BMC Cancer
. 2011
;11
:436
. 13.
Sestak
I
, Cuzick
J
, Sapunar
F
, Eastell
R
, Forbes
JF
, Bianco
AR
, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis
. Lancet Oncol
. 2008
;9
(9
):866
–72
. 14.
Mieog
JS
, Morden
JP
, Bliss
JM
, Coombes
RC
, van de Velde
CJH
; IES Steering Committee
. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 Years of tamoxifen: a retrospective analysis of the intergroup exemestane study
. Lancet Oncol
. 2012
;13
(4
):420
–32
. 15.
Gupta
A
, Henry
NL
, Loprinzi
CL
. Management of aromatase inhibitor-induced musculoskeletal symptoms
. JCO Oncol Pract
. 2020
;16
(11
):733
–9
. 16.
Hershman
DL
, Loprinzi
C
, Schneider
BP
. Symptoms: aromatase inhibitor induced arthralgias
. Adv Exp Med Biol
. 2015
;862
:89
–100
. 17.
Romero
SA
, Su
HI
, Satagopan
J
, Li
QS
, Seluzicki
CM
, Dries
A
, et al. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
. Breast
. 2020
;49
:48
–54
. 18.
Henry
NL
, Conlon
A
, Kidwell
KM
, Griffith
K
, Smerage
JB
, Schott
AF
, et al. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor-treated women with early-stage breast cancer
. J Pain
. 2014
;15
(5
):468
–75
. 19.
Roberts
KE
, Adsett
IT
, Rickett
K
, Conroy
SM
, Chatfield
MD
, Woodward
NE
. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
. Cochrane Database Syst Rev
. 2022
;2022
(1
):CDo13167
. 20.
Roberts
KE
, Rickett
K
, Feng
S
, Vagenas
D
, Woodward
NE
. Exercise therapy for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer
. Cochrane Database Syst Rev
. 2022
;1
(1
):CD012988
. 21.
Woolf
CJ
. Central sensitization: implications for the diagnosis and treatment of pain
. Pain
. 2011
;152
(3 Suppl l
):S2
–15
. 22.
Latremoliere
A
, Woolf
CJ
. Central sensitization: a generator of pain hypersensitivity by central neural plasticity
. J Pain
. 2009
;10
(9
):895
–926
. 23.
Fernandez-Lao
C
, Cantarero-Villanueva
IC
, Fernandez-de-las-Penas
C
, Del-Moral-Ávila
R
, Menjón-Beltrán
S
, Arroyo-Morales
M
. Widespread mechanical pain hypersensitivity as a sign of central sensitization after breast cancer surgery: comparison between mastectomy and lumpectomy
. Pain Med
. 2011
;12
(1
):72
–8
. 24.
Rasmussen
GHF
, Madeleine
P
, Arroyo-Morales
M
, Voigt
M
, Kristiansen
M
. Pain sensitivity and shoulder function among breast cancer survivors compared to matched controls: a case-control study
. J Cancer Surviv
. 2023
;17
(1
):150
–9
. 25.
Manfuku
M
, Nishigami
T
, Mibu
A
, Tanaka
K
, Kitagaki
K
, Sumiyoshi
K
. Comparison of central sensitization-related symptoms and health-related quality of life between breast cancer survivors with and without chronic pain and healthy controls
. Breast Cancer
. 2019
;26
(6
):758
–65
. 26.
Hurth
A
, Nijzink-Ter Steege
J
, Scheepbouwer
P
, Roose
E
, Lahousse
A
, Leysen
L
, et al. Assessment of central sensitization in breast cancer survivors: convergent validity and use of the central sensitization inventory (CSI) and its short-form as a clustering tool
. Clin Pract
. 2021
;11
(3
):607
–18
. 27.
De la Rosa-Diaz
I
, Barrero-Santiago
L
, Acosta-Ramirez
P
, Martín-Peces-Barba
M
, Iglesias-Hernández
E
, Plisset
B
, et al. Cross-sectional comparative study on central sensitization-psychosocial associated comorbidities and psychological characteristics in breast cancer survivors with nociceptive pain and pain with neuropathic features and without pain
. Life
. 2022
;12
(9
):1328
. 28.
Dams
L
, Van der Gucht
E
, Haenen
V
, Lauwers
M
, De Pauw
S
, Steurs
T
, et al. Biopsychosocial risk factors for pain and pain-related disability 1 year after surgery for breast cancer
. Support Care Cancer
. 2022
;30
(5
):4465
–75
. 29.
Manfuku
M
, Nishigami
T
, Mibu
A
, Yamashita
H
, Imai
R
, Kanamori
H
, et al. Predictors of persistent post-surgical pain intensity and interference at 1 year after breast cancer surgery: assessing central sensitization, central sensitivity symptoms, and psychological factors
. Breast Cancer
. 2023
;30
(2
):271
–81
. 30.
Boonstra
A
, van Zadelhoff
J
, Timmer-Bonte
A
, Ottevanger
PB
, Beurskens
CHG
, van Laarhoven
HWM
. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers
. Cancer Nurs
. 2013
;36
(1
):52
–9
. 31.
Mayer
TG
, Neblett
R
, Cohen
H
, Howard
KJ
, Choi
YH
, Williams
MJ
, et al. The development and psychometric validation of the central sensitization inventory
. Pain Pract
. 2012
;12
(4
):276
–85
. 32.
Tanaka
K
, Nishigami
T
, Mibu
A
, Manfuku
M
, Yono
S
, Shinohara
Y
, et al. Validation of the Japanese version of the Central Sensitization Inventory in patients with musculoskeletal disorders
. PLoS One
. 2017
;12
:e0188719
. 33.
Cuesta-Vargas
AI
, Neblett
R
, Nijs
J
, Chiarotto
A
, Kregel
J
, van Wilgen
CP
, et al. Establishing central sensitization-related symptom severity subgroups: a multicountry study using the central sensitization inventory
. Pain Med
. 2020
;21
(10
):2430
–40
. 34.
Scerbo
T
, Colasurdo
J
, Dunn
S
, Unger
J
, Nijs
J
, Cook
C
. Measurement properties of the central sensitization inventory: a systematic review
. Pain Pract
. 2018
;18
(4
):544
–54
. 35.
Peduzzi
P
, Concato
J
, Kemper
E
, Holford
TR
, Feinstein
AR
. A simulation study of the number of events per variable in logistic regression analysis
. J Clin Epidemiol
. 1996
;49
(12
):1373
–9
. 36.
Leysen
L
, Adriaenssens
N
, Nijs
J
, Pas
R
, Bilterys
T
, Vermeir
S
, et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain
. Pain Pract
. 2019
;19
(2
):183
–95
. 37.
Iwata
H
, Nakamura
S
, Toi
M
, Shin
E
, Masuda
N
, Ohno
S
, et al. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fl uorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma
. Breast Cancer
. 2005
;12
(2
):99
–103
. 38.
Abu-Khalaf
MM
, Windsor
S
, Ebisu
K
, Salikooti
S
, Ananthanarayanan
G
, Chung
GG
, et al. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer
. Oncology
. 2005
;69
(5
):372
–83
. 39.
Folkerd
EJ
, Dixon
JM
, Renshaw
L
, A’Hern
RP
, Dowsett
M
. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer
. J Clin Oncol
. 2012
;30
(24
):2977
–80
. 40.
Yunus
MB
. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes
. Semin Arthrits Rheum
. 2007
;36
(6
):339
–56
. 41.
Mao
H
, Bao
T
, Shen
X
, Li
Q
, Seluzicki
C
, Im
EO
, et al. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors
. Eur J Cancer
. 2018
;101
:47
–54
. 42.
Bauml
J
, Chen
L
, Chen
J
, Boyer
J
, Kalos
M
, Li
SQ
, et al. Arthralgia among women taking aromatase inhibitors: is there a sheared inflammatory mechanisms with co-morbid fatigue and insomnia
. Breast Cancer Res
. 2015
;17
(1
):89
. 43.
Laroche
F
, Coste
J
, Medkour
T
, Cottu
PH
, Pierga
JY
, Lotz
JP
, et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study
. J Pain
. 2014
;15
(3
):293
–303
. 44.
Zhu
Y
, Loggia
ML
, Edwards
RR
, Flowers
KM
, Muñoz-Vergara
DW
, Partridge
AH
, et al. Increased clinical pain locations and pain sensitivity in women after breast cancer surgery influence of aromatase inhibitor therapy
. Clin J Pain
. 2022
;38
(12
):721
–9
. 45.
Nijs
J
, Leysen
L
, Vanlauwe
J
, Logghe
T
, Ickmans
K
, Polli
A
, et al. Treatment of central sensitization in patients with chronic pain: time for change
. Expert Opin Pharmacother
. 2019
;20
(16
):1961
–70
. 46.
Clauw
DJ
, Essex
MN
, Pitman
V
, Jones
KD
. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management
. Postgrad Med
. 2019
;131
(3
):185
–98
. 47.
Skljarevski
V
, Desaiah
D
, Liu-Seifert
H
, Zhang
Q
, Chappell
AS
, Detke
MJ
, et al. Efficacy and safety of duloxetine in patients with chronic low back pain
. Spine
. 2010
;35
(13
):E578
–85
. 48.
Moore
RA
, Derry
S
, Aldington
D
, Cole
P
, Wiffen
PJ
. Amitriptyline for fibromyalgia in adults
. Cochrane Database Syst Rev
. 2015
;2019
(5
):Cd011824
. 49.
Hayashida
KI
, Obata
H
. Strategies to treat chronic pain and strengthen impaired descending Noradrenergic inhibitory system
. Int J Mol Sci
. 2019
;20
(4
):822
. 50.
Lepri
B
, Romani
D
, Storari
L
, Barbari
V
. Effectiveness of pain neuroscience education in patients with chronic musculoskeletal pain and central sensitization: a systematic review
. Int J Environ Res Public Health
. 2023
;20
(5
):4098
. 51.
Manfuku
M
, Nishigami
T
, Mibu
A
, Yamashita
H
, Imai
R
, Tanaka
K
, et al. Effect of perioperative pain neuroscience education in patients with post-mastectomy persistent pain: a retrospective, propensity score-matched study
. Support Care Cancer
. 2021
;29
(9
):5351
–9
. 52.
Morales
L
, Pans
S
, Verschueren
K
, Van Calster
B
, Paridaens
R
, Westhovens
R
, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome
. J Clin Oncol
. 2008
;26
(19
):3147
–52
. 53.
Lintermans
A
, Van Calster
B
, Van Hoydonck
M
, Pans
S
, Verhaeghe
J
, Westhovens
R
, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis
. Ann Oncol
. 2011
;22
(8
):1763
–9
. 54.
Hack
CC
, Häberle
L
, Brucker
SY
, Janni
W
, Volz
B
, Loehberg
CR
, et al. Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
. Breast
. 2020
;50
:11
–8
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
